Denali Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
DNLI$20.33+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $60,574 | $127,106 |
| Short-term marketable securities | 876,295 | 907,405 |
| Prepaid expenses and other current assets | 36,706 | 29,626 |
| Total current assets | 973,575 | 1,064,137 |
| Long-term marketable securities | 490,723 | — |
| Property and equipment, net | 46,863 | 45,589 |
| Operating lease right-of-use asset | 25,309 | 26,048 |
| Other non-current assets | 44,621 | 18,143 |
| Total assets | $1,581,091 | $1,153,917 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $11,855 | $9,483 |
| Accrued clinical and other research & development costs | 19,956 | 19,035 |
| Accrued manufacturing costs | 16,720 | 15,462 |
| Other accrued costs and current liabilities | 5,986 | 5,152 |
| Accrued compensation | 8,053 | 21,590 |
| Operating lease liability, current | 7,512 | 7,260 |
| Deferred research funding liability, current | 12,500 | — |
| Total current liabilities | 82,582 | 77,982 |
| Operating lease liability, less current portion | 43,034 | 44,981 |
| Total liabilities | 125,616 | 122,963 |
| Commitments and contingencies (Note 6) | ||
| Stockholders' equity: | ||
| Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.01 par value; 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 142,512,856 shares and 138,385,498 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 1,751 | 1,711 |
| Additional paid-in capital | 2,673,033 | 2,144,811 |
| Accumulated other comprehensive income (loss) | (1,296) | 643 |
| Accumulated deficit | (1,218,013) | (1,116,211) |
| Total stockholders' equity | 1,455,475 | 1,030,954 |
| Total liabilities and stockholders’ equity | $1,581,091 | $1,153,917 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.